Sakar Healthcare Share Price Forecast to 2030
- July 27, 2026
- Posted by: Neeraj Pandey
- Category: News
Sakar Healthcare share price Rs 802.00. 52W high Rs 960.00, low Rs 311.00. Market cap Rs 1785Cr. Cr. 2030 scenario range Rs 601.50 to Rs 1,444.
Sakar Healthcare manufactures pharmaceutical formulations and APIs for domestic and export markets. As a listed player in the Pharmaceuticals segment, Sakar Healthcare’s share price trajectory over the next three years will be shaped by rising domestic and export demand for its pharmaceutical formulation and API portfolio. Understanding the interplay of these growth drivers and risk factors is essential for investors evaluating this stock.
Sakar Healthcare Share Price Today and Key Metrics
| Metric | Value |
|---|---|
| Current Price | ₹802.00 |
| 52-Week High / Low | ₹960 – ₹311 |
| Market Cap | ₹ 1,785 Cr. |
| P/E Ratio | 49.5 |
| Book Value | ₹ 146 |
| Return on Equity (ROE) | 9.99 % |
| Return on Capital Employed (ROCE) | 12.7 % |
| Dividend Yield | 0.00 % |
Sakar Healthcare is currently trading at ₹802.00. The stock has a 52-week range of ₹960 – ₹311, reflecting the price band within which it has moved over the past year. The current P/E ratio of 49.5 provides a baseline for valuation comparison with peers in the Pharmaceuticals space.
Log in to Univest to access stock insights and portfolio tracking for Sakar Healthcare.
Key Factors Driving Sakar Healthcare Share Price
The primary growth catalyst for Sakar Healthcare is rising domestic and export demand for its pharmaceutical formulation and API portfolio. This driver is anchored in structural trends within the Pharmaceuticals sector, which remains a focus area for domestic institutional investors and analysts tracking India’s growth story.
Sector peers including Morepen Laboratories, Bafna Pharmaceuticals, Jagsonpal Pharmaceuticals operate in similar addressable markets and provide useful benchmarks for valuation and growth trajectories. Monitoring these peers alongside Sakar Healthcare’s own quarterly disclosures offers a more complete picture of the competitive landscape.
Risk Factors to Watch
Investors in Sakar Healthcare must account for the following: regulatory compliance in pharma manufacturing and client concentration are key risks. These risks are not unique to Sakar Healthcare and affect the broader Pharmaceuticals segment, but the degree to which they impact Sakar Healthcare specifically depends on its balance sheet strength, client diversification, and management execution.
Sakar Healthcare Share Price Forecast: 3-Year Scenarios
The following indicative scenario analysis is based on illustrative assumptions and is not a research-grade price target. Actual outcomes will depend on company performance, sector dynamics, and macroeconomic conditions.
| Scenario | 3-Year Indicative Range | Key Assumptions |
|---|---|---|
| Bull Case | ₹1,444 | Strong execution on growth plans, sector tailwinds materialise, margin expansion driven by operating leverage |
| Base Case | ₹1,083 | Steady growth broadly in line with sector, manageable input cost pressures and stable demand conditions |
| Bear Case | ₹601.50 | Demand slowdown, margin compression from rising costs, or sector-specific headwinds materialise |
These ranges are illustrative only and do not constitute research or investment advice. The bull case assumes the key growth drivers materialise fully, while the bear case reflects meaningful headwinds. The base case represents a more moderate, sector-average outcome.
Consult a SEBI-registered investment adviser before making any investment decisions in this stock.
Investor Considerations for Sakar Healthcare
Before investing in Sakar Healthcare, consider the following: First, assess the company’s competitive moat within the Pharmaceuticals segment. Second, evaluate the balance sheet quality, specifically the debt-to-equity ratio and coverage ratios. Third, track the management’s guidance on growth and margins in recent investor communications.
The Pharmaceuticals index provides a sector benchmark to assess whether Sakar Healthcare is outperforming or underperforming its peers on a risk-adjusted basis. Retail investors are always advised to compare multiple data points, including Screener.in fundamentals, NSE filings, and SEBI disclosures, before forming an investment view.
Download the Univest app for real-time stock data, research, and portfolio management.
How to Evaluate Sakar Healthcare Share Price Performance
Assessing the Sakar Healthcare share price over a multi-year horizon requires tracking both company-specific and sector-level indicators. Key metrics that typically correlate with share price movement in the Pharmaceuticals segment include revenue growth, operating margin trajectory, return on capital employed, and balance sheet leverage. Investors tracking the Sakar Healthcare share price should monitor these across quarterly filings.
The 52-week high and low of the Sakar Healthcare share price provide a useful anchoring range for near-term valuation assessment. A share price trading close to its 52-week low may reflect sector headwinds or company-specific stress, while a share price near its 52-week high could suggest strong momentum or overextension relative to fundamentals. Neither extreme is a buy or sell signal on its own.
Comparing the Sakar Healthcare share price trend with peers in the same sector, and with the relevant sector index, helps investors understand whether underperformance or outperformance is idiosyncratic or part of a broader sectoral move. This relative analysis is a core part of any disciplined share price evaluation framework.
Frequently Asked Questions: Sakar Healthcare Share Price
What is Sakar Healthcare’s share price today?
As of the latest available data, Sakar Healthcare (SAKAR) is trading at ₹802.00 on the NSE. The 52-week range is ₹960 – ₹311. For real-time prices, check the Univest app or NSE website.
What is the Sakar Healthcare share price forecast for the next 3 years?
A specific share price projection for Sakar Healthcare over the next three years depends on revenue growth, margin improvement and sector conditions. Investors should track quarterly results and consult a SEBI-registered adviser for personalised analysis.
Is Sakar Healthcare a good stock to buy for the long term?
Sakar Healthcare operates in the Pharmaceuticals sector. Long-term investment decisions should be based on the company’s business fundamentals, competitive positioning, and your individual risk profile and investment horizon.
What factors drive Sakar Healthcare share price?
Key drivers include rising domestic and export demand for its pharmaceutical formulation and API portfolio, quarterly earnings results, sector trends in Pharmaceuticals, and broader market conditions.
What are the risks of investing in Sakar Healthcare?
Key risks include regulatory compliance in pharma manufacturing and client concentration are key risks. Equity investments carry market risk, and past performance is no guarantee of future results.
What is Sakar Healthcare’s P/E ratio?
Sakar Healthcare’s current price-to-earnings ratio is 49.5. Comparing this with sector peers in the Pharmaceuticals space helps assess relative valuation.
How does Sakar Healthcare compare to its peers?
Sakar Healthcare competes with players such as Morepen Laboratories, Bafna Pharmaceuticals in the Pharmaceuticals segment. Peer comparisons on revenue growth, margin profile and valuation multiples are useful inputs before making any investment decision.
